Skip to content

Advertisement

  • Research article
  • Open Access
  • Open Peer Review

Pathogenic copy number variants and SCN1A mutations in patients with intellectual disability and childhood-onset epilepsy

  • 1, 2Email author,
  • 3,
  • 3,
  • 3,
  • 4,
  • 5,
  • 1,
  • 1,
  • 1,
  • 1,
  • 6,
  • 1, 2,
  • 1,
  • 1,
  • 7,
  • 7,
  • 7,
  • 8,
  • 8,
  • 9,
  • 10,
  • 11,
  • 11,
  • 11,
  • 3,
  • 3,
  • 3,
  • 1 and
  • 3, 5
BMC Medical GeneticsBMC series – open, inclusive and trusted201617:34

https://doi.org/10.1186/s12881-016-0294-2

  • Received: 20 October 2015
  • Accepted: 14 April 2016
  • Published:
Open Peer Review reports

Abstract

Background

Copy number variants (CNVs) have been linked to neurodevelopmental disorders such as intellectual disability (ID), autism, epilepsy and psychiatric disease. There are few studies of CNVs in patients with both ID and epilepsy.

Methods

We evaluated the range of rare CNVs found in 80 Welsh patients with ID or developmental delay (DD), and childhood-onset epilepsy. We performed molecular cytogenetic testing by single nucleotide polymorphism array or microarray-based comparative genome hybridisation.

Results

8.8 % (7/80) of the patients had at least one rare CNVs that was considered to be pathogenic or likely pathogenic. The CNVs involved known disease genes (EHMT1, MBD5 and SCN1A) and imbalances in genomic regions associated with neurodevelopmental disorders (16p11.2, 16p13.11 and 2q13). Prompted by the observation of two deletions disrupting SCN1A we undertook further testing of this gene in selected patients. This led to the identification of four pathogenic SCN1A mutations in our cohort.

Conclusions

We identified five rare de novo deletions and confirmed the clinical utility of array analysis in patients with ID/DD and childhood-onset epilepsy. This report adds to our clinical understanding of these rare genomic disorders and highlights SCN1A mutations as a cause of ID and epilepsy, which can easily be overlooked in adults.

Keywords

  • Array comparative genomic hybridization
  • Intellectual disability
  • Epilepsy
  • Copy number variation
  • SCN1A

Background

Copy number variants (CNVs; chromosomal deletions and duplications) have been identified as significant aetiological factors in a range of neurodevelopmental disorders including intellectual disability (ID) [1], autism [2], epilepsy [3] and psychiatric disease [4]. The detection of a causative CNV in a patient is valuable for genetic counselling and, in some cases, guiding clinical management. The observation of a rare chromosomal abnormality in a patient with a rare neurological phenotype has occasionally been the vital clue leading to the identification of genes and pathways critical to brain development [5, 6]. A limited number of previous genome-wide CNV studies have focused on patients with both epilepsy and ID [710]. We set out to investigate the rare CNVs present in a series of 80 patients with ID/developmental delay (DD) and childhood-onset epilepsy. Our aims were: to determine the frequency of pathogenic CNVs in the cohort; to define the clinical features of patients carrying pathogenic CNVs; to identify any sub-groups of patients particularly enriched for pathogenic CNVs; and to highlight candidate genes for epilepsy and ID/DD.

Methods

Study subjects

Participants were recruited between 2010 and 2014. Participants were 80 unrelated patients (49 adults and 31 children) identified through medical genetics, learning disability and paediatric neurology clinics around Wales (see Additional file 1: Table S1 for further demographic information). Participants lacked a molecular diagnosis and had not previously undergone high resolution genome-wide cytogenetic analysis (<1 Mb resolution). The majority of participants had previously been tested by karyotype (61/80) combined with additional cytogenetic and molecular tests (Additional file 1: Table S2). Patients with known significant congenital brain malformations were excluded (e.g. malformations of cortical development, porencephaly, holoprosencephaly or intracerebral vascular malformations). CNV rates in the general population were estimated from 929 control subjects derived from the Wellcome Trust Case Control Consortium 2 National Blood Donors Cohort [11]. These were blood donors recruited by UK Blood Services and are therefore similar in ethnic origin to our mostly white British cohort. Controls were genotyped on Illumina OmniExpress single nucleotide polymorphism (SNP)-arrays.

Ethics approval and consent to participate

The study was approved by the Research Ethics Committee for Wales (09/MRE09/51). Informed consent for testing and publication was obtained from all participants (or their parents/legal guardians).

Microarray analysis

Genomic DNA was extracted from blood (n = 73) or saliva (n = 7). Samples were tested on one of three platforms: (i) Illumina610-Quad SNP-array (n = 20); (ii) Illumina OmniExpress SNP-array (n = 36); or (iii) microarray-based comparative genomic hybridization (array CGH) using a BlueGnome CytoChip ISCA 8x60k v2.0 array (n = 24). Validation testing was performed by fluorescent in situ hybridisation, multiplex ligation-dependent probe amplification (MLPA) or by testing on a second array platform. The method for identifying CNVs depended on the array platform. SNP-array data was called using PennCNV [12]. Called CNVs were filtered by probe number (10 or more) and gene content (at least one). We excluded CNVs which had 50 % or greater overlap with a CNV in the control cohort. However, for key genomic regions known to harbour recurrent CNVs associated with neurodevelopmental disorders which demonstrate incomplete penetrance (1q21.1, 15q11.2, 15q13.3, 16p11.2 and 16p13.11) we allowed CNVs to be present at low frequency in controls (<1 %). Analysis focused on deletions and duplications larger than 100 kb and 250 kb respectively (50 kb for disease regions). Array CGH data was referenced against same sex control DNA (Promega) and analysed using Illumina BlueFuse Multi (v3.1) software, with data filtered on consecutive probes (3 or more) and size (as above). Imbalances detected by array CGH were interpreted by comparison with data from the Database of Genomic Variants, International Standards for Cytogenomic Arrays consortium and local laboratory data. Coordinates are based on hg19/GRCh37. Statistical comparisons were made using Fisher’s exact test calculated with an online tool [13]. Parents and additional family members were analysed, where available, to determine if a CNV had arisen de novo or segregated with disease in a family. We assessed the clinical significance of CNVs based on their size, type, inheritance and whether they contained known disease genes. We were guided by the approach set out in previous publications [7, 14]. Based on this assessment some CNVs were annotated as ‘pathogenic’ (e.g. a de novo deletion of a proven disease gene/region) or ‘likely pathogenic’ (e.g. large CNVs containing genes/regions previously linked to disease). Other CNVs were considered to be of unknown significance.

SCN1A gene testing

A subgroup of patients was tested for intragenic SCN1A mutations. Sequencing of the complete coding region and flanking sequence of the gene was performed by bidirectional Sanger sequencing (n = 4) or by targeted next-generation sequencing (NGS) (n = 11). Sequencing (Sanger or NGS) covered all the coding sequence of SCN1A along with 20 bp of flanking intron or untranslated region (UTRs). Sequencing did not cover the promoter, deep intronic regions or the rest of the UTRs. In silico analysis of detected variants included PhyloP [15], SIFT [16], Grantham distance [17], PolyPhen-2 [18] and CADD [19]. We also searched the Exome Aggregation Consortium (ExAC) database [20], dbSNP [21], ClinVar [22] and an SCN1A mutation-specific database [23]. Nucleotide and protein positions are based on NCBI Reference Sequences NM_001165963.1 and NP_001159435.1 respectively [24].

Results and discussion

The 80 patients had a range of epilepsy phenotypes including epileptic encephalopathy (EE, n = 25), non-lesional focal epilepsies (n = 22), and genetic generalised epilepsy with ID (GGE-ID, n = 22) (Table 1). In the remainder, the epilepsy phenotype was unclassified or unknown. We found 22.5 % (18/80) of the cohort carried at least one rare CNV (Table 2). Three patients had more than one rare CNV. The average size of the CNVs was 647 kb (median 488 kb). We identified 8 CNVs considered to be likely (n = 3) or clearly pathogenic (n = 5) (Table 2). One patient (R660) had one clearly and one likely pathogenic CNV. This meant 7 (8.8 %) of our patients had pathogenic or likely pathogenic CNVs. Additional rare variants of uncertain clinical significance (VUS) were present in 11 further patients. We compared the frequency of CNVs in patients and controls. We found that large (>500 kb) low frequency (<1 %) genic CNVs were marginally more common in patients (13 %, 10/80) compared with controls (11 %, 105/929). However, this difference was not statistically significant (P = 0.71). The majority of patients had previously been tested by karyotype which will have depleted larger CNVs from the cohort.
Table 1

Epilepsy syndromes in the cohort at recruitment

Syndrome

Number

Epileptic encephalopathy (EE)

 Lennox-Gastaut syndrome

9

 Dravet syndrome

3

 West syndrome

2

 Myoclonic astatic epilepsy

2

 Epilepsy of infancy with migrating focal seizures

2

 Ohtahara syndrome

1

 Epilepsy with continuous spikes and waves during sleep

1

 Unclassified EE with onset in infancy

5

Genetic generalised epilepsy with intellectual disability (GGE-ID)

 Myoclonic epilepsy

3

 Progressive myoclonic epilepsy

1

 Other GGE-IDs

18

Non-lesional focal epilepsies

22

Unclassified epilepsy

2

Unknown

9

Total

80

Table 2

Rare CNVs detected in 80 patients with ID/DD and epilepsy

Subject

Age

Sex

Clinical features

Seizure onset

Syndrome

Seizure types

Cytoband

CNV Type

Coordinates

Size (Kb)

Tests

Status

Interpretation

Genes

R125

10 m

F

Severe DD, cleft palate

3 m

EIMFS

FE, EBCS, CSE

2q24.3

Del

163823021–167958723

4,136

c/f

DN

Path

SCN3A, SCN2A, SCN1A, SCN9A, SCN7A & 8 others

R351

15y

M

Moderate DD, poor coordination, joint contractures, mildly dysmorphic

3 m

Dravet

FS, GTCS, CSE, M

2q24.3

Del

166842637–166918932

76

c/d

DN

Path

SCN1A

R404

7y

F

Mild DD, ASD

8 m

West

IS, Abs

16p11.2

Del

29595483–30198151

603

b/e,f

DN

Path

DOC2A, KIF22, MAPK3, PRRT2, QPRT, SEZ6L2 & 24 others

R660

21y

M

Mod-severe ID, challenging behaviour, ASD, depression, dysmorphic

8 m

GGE-ID

Abs, M, FDS, EBCS

9q34.3

Del

140707889–140890373

182

b/e

DN

Path

CACNA1B, EHMT1

      

3p14.2

Dup

59736299–61023355

1,287

b/e

Pat

Likely

FHIT

      

3p22.1

Del

41359533–41824555

465

b/e

Mat

VUS

ULK4

R911

22y

F

Mod ID, small head, mildly dysmorphic

10y

FE

FDS, GTCS

2q22.3

Del

148691873–148818437

127

b/e

DN

Path

MBD5, ORC4

R913

20y

M

Mod-severe ID, challenging behaviour, ASD

10 m

FE

FS, FDS, EBCS

16p13.11

Dup

15512574–16262571

750

b/e

Mat

Likely

ABCC1, C16orf45, FOPNL, KIAA0430, MIR484, MYH11, NDE1

R345

27y

F

Mild ID, dysmorphic

<6y

GGE-ID

M, Abs, GTCS

2q13

Del

111392259–113094793

1,703

b/e

Pat

Likely

BUB1, BCL2L11, ANAPC1, MERTK, FBLN7 & 5 others

R58

26y

F

Severe ID, scoliosis

<8y

GGE-ID

At, Abs, M

1q21.1

Dup

145625979–145723645

98

a/e

Mat

VUS

CD160, RNF115

R74a

51y

F

Mild-mod ID, depression

3 m

FE

FS, FE, EBCS

1p21.1

Del

104167778–104297867

130

a/e

U

VUS

AMY1A, AMY1B, AMY1C, AMY2A

R101

32y

M

ID, seizures

<16y

U

U

11q22.3

Del

109173027–109325299

152

b/e

Pat

VUS

C11orf87

R198

19y

M

Severe ID, ASD, mild right hemiparesis

7 m

LGS

FE, IS, Abs, NCS, GTCS, At, FDS

Xq28

Del

150589930–150811921

222

c/nd

U

VUS

PASD1

R528

23y

M

Severe ID, challenging behaviour, ASD, dysmorphic, regression

11y

FE

FE, Abs

15q13.3

Dup

32019919–32514341

494

b/e

U

VUS

CHRNA7

R605

41y

M

ID, seizures

<16y

U

U

15q11.2

Dup

22383292–23272733

889

b/e

Pat

VUS

CYFIP1, NIPA1, NIPA2, TUBGCP5 & 8 others

       

8p23.1

Del

11713852–12204679

491

b/e

Mat

VUS

CTSB, FAM66D, FAM86B1, USP17L2, ZNF705D & 6 others

R622a

28y

F

Moderate ID, challenging behaviour

6 m

GGE-ID

IS, GTCS, M

18p11.22

Dup

10042023–10581304

539

b/e

Mat

VUS

APCDD1, NAPG

R650

21y

M

Mild ID, thin habitus, depression

18 m

GGE-ID

Abs, M, GTCS

15q13.3

Dup

32029693–32514926

485

a/nd

U

VUS

CHRNA7

      

15q14

Del

34700297–34807869

108

a/nd

U

VUS

GOLGA8A

R786

9y

M

Moderate DD, Leg hypertonia, dystonia

2y

GGE-ID (M)

M, Abs, At

21q21.3

Del

27715263–27955385

240

a/e

Mat

VUS

CYYR1

R931

15y

F

Severe DD, ASD, dysmorphic, microcephaly

12y

GGE-ID

GTCS

7q11.22

Del

71815170–72305671

491

b/e

Pat

VUS

CALN1, MIR4650-1, MIR4650-2, SBDSP1, TYW1B

R981

5y

F

Severe DD, regression, ASD, leg hypertonia

1w

GGE-ID

Abs, At, M, T

3p26.3

Dup

726675-1301830

575

c/nd

U

VUS

CNTN6

Age (at recruitment) and seizure onset in y(ears), m(onths) or w(eeks). Clinical features: ID intellectual disability, DD, developmental delay, ASD autism spectrum disorder

Syndrome, electroclinical syndrome or main epilepsy type at recruitment: Dravet, Dravet syndrome; EIMFS, epilepsy of infancy with migrating focal seizures: FE focal epilepsy, GGE-ID, genetic generalised epilepsy with ID, LGS Lennox-Gastaut syndrome, U unknown, West West syndrome

Seizure types: Abs absence, At atonic, CSE convulsive status epilepticus, EBCS evolution to bilateral or convulsive seizures, FDS focal dyscognitive seizures, FS febrile seizures, GTCS generalised tonic-clonic seizures, IS infantile spasms, M myoclonic, NCS non-convulsive status epilepticus, T tonic, seizure type at presentation is underlined (when known)

CNV type, Dup(lication) or Del(eletion). Coordinates, chromosome position of first/last abnormal probes based on hg19/GRCh37. Tests, primary array/confirmation method: (a) Illumina610-Quad SNP-array, (b) Illumina OmniExpress SNP-array, (c) BlueGnome CytoChip array CGH, (d) quantitative PCR, (e) Illumina Exome BeadChip or custom Illumina SNP array, (f) fluorescence in situ hybridization, and (nd) not done. Status: DN, de novo; inherited Pat(ernally); Mat(ernally) or U(nknown). Interpretation (of clinical significance): Path(ogenic); Likely, likely pathogenic; VUS, variant of uncertain significance

aPatients R622 and R74 had pathogenic SCN1A mutations which suggests these two CNVs are likely to be benign

Pathogenic CNVs

The five clearly pathogenic CNVs were all de novo deletions. We found a de novo 127 kb deletion of 2q23.1 in a woman with moderate ID, mildly dysmorphic facial features (long face, thin upper lip, slightly upslanting palpebral fissures, long nose) and seizures. The deletion disrupted the first two non-coding exons of the MBD5 gene. MBD5 encodes a member of the methyl-CpG-binding domain family. The MBD5 protein binds to methylated DNA and is thought to regulate gene expression by controlling chromatin modification [25]. Deletions of the 5′- UTR of MBD5 result in reduced expression of the gene [26]. Common clinical features in MBD5 patients include ID/DD, seizures, language impairment, microcephaly, mild craniofacial dysmorphism and autism spectrum disorders (ASD) [2628]. Interestingly, patients with CNVs confined to the 5′-UTR (like R911) have phenotypes similar to patients with larger 2q23.1 deletions. This highlights the critical impact of non-coding sequence at the locus [29].

We observed a de novo 182 kb deletion at 9q34.3 involving EHMT1 in an adult male (R660) with moderate-to-severe ID, dysmorphic features (hypertelorism, mid face hypoplasia, prognathism), aggressive behaviour, autistic features, depression and epilepsy. Deletions at 9q34 involving EHMT1 are responsible for Kleefstra syndrome [30]. EHMT1 encodes a histone methyltransferase involved in transcriptional repression. EHMT1 is known to interact with MBD5 and they work together to regulate gene expression [25]. Characteristic features of Kleefstra syndrome include ID/DD, microcephaly, psychiatric disorders, severe behavioural problems, dysmorphic features, hypotonia, heart defects and seizures [31]. In addition to truncating EHMT1 the 9q34 deletion involved the adjacent CACNA1B gene. CACNA1B encodes a subunit of a voltage-dependent calcium channel expressed on neurons. Mutations in other N-type voltage-dependent calcium channel subunits have been linked to a wide range of paroxysmal disorders including periodic paralysis [32], familial hemiplegic migraine [33], myoclonus-dystonia syndrome [34], childhood absence epilepsy [35] and idiopathic generalized epilepsy [36]. Therefore, it is possible that haploinsufficiency of CACNA1B may have contributed to the patient’s epilepsy phenotype. Patient R660 also had a paternally-inherited 1.3 Mb duplication involving the FHIT gene (considered to be likely pathogenic). The FHIT gene is a member of the histidine triad gene family. FHIT encodes diadenosine 5′,5‴-P1,P3-triphosphate hydrolase, an enzyme involved in purine metabolism. Rare CNVs involving FHIT have previously been described in autism [37, 38]. R660 carried a third rare CNV, a maternally-inherited 465 kb deletion at 3p22.1 involving ULK4. ULK4 encodes a serine/threonine kinase. Expression of the ULK4 gene is neuron-specific and developmentally regulated [39]. This third CNV was considered to be a VUS, although deletions in ULK4 have recently been reported as a potential risk factor for schizophrenia [39].

The third clearly pathogenic CNV was a de novo 603 kb 16p11.2 deletion in a girl with mild DD, ASD and infantile spasms (seizure free following treatment). Seizures are a common feature of 16p11.2 deletion syndrome along with ASD, ID/DD, psychiatric disease and increased risk of obesity [40, 41]. The reciprocal duplications at 16p11.2 locus have also been associated with epilepsy including infantile spasms [7, 42]. The last two clearly pathogenic CNVs were both de novo deletions at 2q24.3: one was 76 kb in size and deleted exons 4 to 28 of the SCN1A gene; the other was 4.1 Mb and deleted 13 genes including SCN1A. SCN1A encodes a voltage-gated sodium channel which is essential for the generation and propagation of action potentials in neurons. Mutations in SCN1A cause a spectrum of seizure disorders including familial febrile seizures, generalised epilepsy with febrile seizures plus and Dravet syndrome (severe myoclonic seizures of infancy) [4345]. Typical features of these disorders are seizure onset in infancy with fever sensitivity. Severe manifestations of SCN1A-related disease include pharmacoresistant seizures, ID/DD, ataxia and autistic behaviour [46, 47]. Patient R125, who had the larger of the two deletions, had a severe phenotype with poor seizure control, severe DD and a cleft palate. These additional features may be due to haploinsufficiency of other genes in the region. The deletion in R125 included SCN2A, SCN3A and SCN9A. All three of these genes encode voltage-gated sodium channels which have been linked to epilepsy [4850]. The patient’s epilepsy phenotype was considered to be epilepsy of infancy with migrating focal seizures (EIMFS). A number of patients with 2q24.3 deletions and EIMFS -like phenotypes have recently been reported [51, 52]. Patient R351, who had the smaller of the 2q24.3 deletions, had previously undergone SCN1A sequencing which had not detected their multi-exon deletion. This highlights that DNA sequencing alone is insensitive to CNVs and that dose-sensitive techniques (e.g. array CGH or MLPA) are required to detect a significant proportion of SCN1A mutations [53].

Two further likely pathogenic CNVs were found. One was a paternally-inherited 1.7 Mb deletion of 2q13 in a female patient (R345) with mild ID, small ventricular septal defect, facial dysmorphism (long face, retrognathism, broad nasal root, hypertelorism, mild facial asymmetry) and epilepsy. Deletions at 2q13, similar to the one found in patient R345 have been reported in other patients with DD/ID [54, 55]. Common manifestations include facial dysmorphism, autistic features, seizures and cardiac malformations. Previously reported 2q13 deletions have been inherited from an apparently normal parent, consistent with incomplete penetrance. Interestingly, the father of R345 shares similar facial features, but has no history of ID or epilepsy. The third likely pathogenic CNV was a maternally-inherited 750 kb duplication of 16p13.11 in a man with mild ID, ASD, seizures and a history of aggressive episodes. We considered the 16p13.11 duplication to be likely contributory as there was a family history of childhood epilepsy in the patient’s mother and a maternal uncle (untested). Deletions in the 16p13.11 region are clear risk factors for neurodevelopmental disorders including epilepsy [3, 56]. There is also evidence that duplications at 16p13.11 predispose to neurodevelopmental disorders (ASD, schizophrenia and ID) [5760] and have been reported in patients with epilepsy [61]. Several further CNVs at genomic ‘hot spots’ were observed (duplications at 1q21.1, 15q11.2 and 15q13.3). These duplications were all inherited from unaffected parents and overlapped CNVs in the control cohort. They were therefore considered to be VUS. It remains possible that some of these VUS have contributed to disease risk. For example, there is evidence that CHRNA7 duplications may subtly increase the risk of neurodevelopmental disorders including ID [62]. However, further large-scale epidemiological studies are required to fully define these risks. Among the non-‘hotspot’ CNVs of uncertain significance we found a 575 kb duplication involving the first 4 exons of CNTN6. This duplication was identified in a 5-year-old girl with severe DD, ASD, bilateral lower limb hypertonia and early-onset seizures. CNTN6 is an interesting candidate gene for neurodevelopmental disorders as it encodes a neural adhesion molecule that operates in the formation, maintenance and plasticity of neuronal networks. In addition, CNVs involving CNTN6 have been reported in patients with DD/ID and autistic features [2, 6365].

SCN1A mutations

Struck by finding two deletions involving SCN1A we realised that this key monogenic cause of epilepsy had not been extensively pre-screened in our cohort (only 9/80). The majority of recruits were adults (n = 49) who were initially investigated before SCN1A testing was available. Furthermore, in contrast to paediatric settings, the significance of SCN1A mutations for adult patients is often neglected [66], usually because key elements of early history (e.g. age of onset, initial seizure types) are not available. We therefore selected a group of patients with early-onset epilepsy for SCN1A sequencing. Of the 38 patients with seizure onset before 12 months, 6 had previously had normal testing for SCN1A while 3 others had pathogenic CNVs. Fifteen of the remaining 29 patients were prioritized for testing based on clinical features (e.g. a history of myoclonic or febrile seizures). This found 4 pathogenic SCN1A mutations (Table 3). All four patients had seizure onset in early infancy (6 months or before) and ongoing seizures despite anticonvulsant therapy. Three of the mutations were missense mutations. The fourth was a 4 base duplication leading to a frameshift early in the gene. In silico analysis indicated the missense mutations were all deleterious changes affecting conserved residues (Table 3). One missense mutation segregated with epilepsy and ID phenotypes in the patient’s family (the proband’s two affected siblings and their mildly-affected mother) the others were all de novo. In combination with the array data these results indicate that at least 6/80 (7 %) of our cohort had SCN1A-related seizure disorders.
Table 3

SCN1A mutations in the cohort

Subject

R622

R74

R710

R769

Age

28y

51y

24y

3y

Sex

F

F

F

F

Clinical features

Moderate ID, challenging behaviour

Mild-mod ID, depression

Moderate ID, ataxia, stroke-like episodes

Mod-severe DD, poor coordination

Seizure onset

6 m

3 m

6 m

5d

Syndrome

GGE-ID

FE

PME

CSWS

Seizure types

IS, GTCS, M

FS, FE, EBCS

C-CSE, M, FDS, EBCS

T, GTCS, CSE, FE, At, Abs, M

Genomic coordinates

Chr2 g.166915177 _166915180dup

Chr2 g.166915162 G > A

Chr2 g.166913001 G > C

Chr2 g.166848780 C > T

cDNA

c.283_286dup

c.301C > T

c.393C > G

c.5005G > A

Protein

p.Gly96Glufs*24

p.Arg101Trp

p.Ser131Arg

p.Ala1669Thr

Inheritance

De novo

De novo

Segregates with phenotype

De novo

PhyloP

-

0.91 (highly conserved)

0.89 (highly conserved)

0.86 (highly conserved)

Grantham distance

-

101 (moderate)

110 (moderate)

58 (small)

SIFT

-

0 (deleterious)

0.02 (deleterious)

0 (deleterious)

PolyPhen-2 (HumVar)

-

0.982 (probably damaging)

0.368 (benign)

1 (probably damaging)

CADD (PHRED-scaled)

-

34 (top 0.1 %)

22.3 (top 1 %)

26.1 (top 1 %)

ExAC frequency

0

0

0

0

dbSNP

-

rs121917965

-

-

Age (at recruitment) and seizure onset in y(ears), m(onths) or d(ays). Clinical features: ID intellectual disability, DD developmental delay

Syndrome, electroclinical syndrome or main epilepsy type at recruitment: CSWS, epilepsy with continuous spikes and waves during sleep; FE focal epilepsy, GGE-ID genetic generalised epilepsy with ID, PME progressive myoclonic epilepsy

Seizure types: Abs absence, At atonic, C clonic, CSE convulsive status epilepticus, EBCS evolution to bilateral or convulsive seizures, FDS focal dyscognitive seizures, FS febrile seizures, GTCS generalised tonic-clonic seizures, IS infantile spasms, M myoclonic, T tonic, seizure type at presentation is underlined. Coordinates are based on hg19/GRCh37. Nucleotide and protein reference sequences were NM_001165963.1 and NP_001159435.1

Conclusions

We have reported the range of rare CNVs found in a series of 80 Welsh patients with childhood-onset epilepsy and ID/DD. We identified clearly or likely pathogenic CNVs in 7 (8.8 %) of the patients including 5 rare de novo deletions. Our results highlight key genes for brain development including drawing attention to SCN1A mutations in adults with early-onset pharmacoresistant epilepsy and ID. Our results contribute additional phenotypic descriptions for these rare genomic disorders and support the use of molecular cytogenetic analysis in the genetic evaluation of patients with ID/DD and epilepsy.

Abbreviations

Array CGH: 

microarray-based comparative genomic hybridization

ASD: 

autism spectrum disorder

CNV: 

copy number variant

DD: 

developmental delay

EIMFS: 

epilepsy of infancy with migrating focal seizures

EE: 

epileptic encephalopathy

ID: 

intellectual disability

GGE: 

genetic generalised epilepsy

MLPA: 

multiplex ligation-dependent probe amplification

NCBI: 

national center for biotechnology information

NGS: 

next-generation sequencing

SNP: 

single nucleotide polymorphism

VUS: 

variant of uncertain clinical significance

Declarations

Acknowledgements

The authors would like to thank the patients, families, clinicians and scientists who contributed to this work. This research was funded by the Baily Thomas Charitable Fund and the Medical Research Council (Centre grant G0800509 and Program grant G0801418). The project was also supported by the Wales Epilepsy Research Network and the National Institute for Social Care and Health Research.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Institute of Medial Genetics, University Hospital of Wales, Cardiff, CF14 4XW, UK
(2)
Institute of Cancer and Genetics, Cardiff University, Cardiff, CF14 4XN, UK
(3)
MRC Centre for Neuropsychiatric Genetics and Genomics, Institute of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, CF24 4HQ, UK
(4)
Llwyneryr Unit, Learning Disability Services, Clasemont Road, Morriston, Swansea, SA6 6AH, UK
(5)
Learning Disabilities Directorate, Abertawe Bro Morgannwg University NHS Trust, Treseder Way, Caerau, Cardiff, CF5 5WF, UK
(6)
Department of Clinical Genetics, Glan Clwyd Hospital, Betsi Cadwaladr University Health Board, Rhyl, Denbighshire, LL18 5UJ, UK
(7)
Department of Paediatric Neurology, University Hospital of Wales, Cardiff, CF14 4XW, UK
(8)
Department of Paediatric Neurology, Morriston Hospital, Abertawe Bro Morgannwg University Health Board, Swansea, SA6 6NL, UK
(9)
Department of Paediatrics, Royal Glamorgan Hospital, Cwm Taf University Health Board, Pontyclun, Mid Glamorgan, CF72 8XR, UK
(10)
Welsh Epilepsy Centre, Neurosciences Directorate, University Hospital of Wales, Cardiff, CF14 4XW, UK
(11)
Neurology and Molecular Neuroscience Research, Institute of Life Science, College of Medicine, Swansea University, Swansea, SA2 8PP, UK

References

  1. Cooper GM, Coe BP, Girirajan S, Rosenfeld JA, Vu TH, Baker C, et al. A copy number variation morbidity map of developmental delay. Nat Genet. 2011;43(9):838–46.View ArticlePubMedPubMed CentralGoogle Scholar
  2. Pinto D, Pagnamenta AT, Klei L, Anney R, Merico D, Regan R, et al. Functional impact of global rare copy number variation in autism spectrum disorders. Nature. 2010;466(7304):368–72.View ArticlePubMedPubMed CentralGoogle Scholar
  3. Mefford HC, Muhle H, Ostertag P, von Spiczak S, Buysse K, Baker C, et al. Genome-wide copy number variation in epilepsy: novel susceptibility loci in idiopathic generalized and focal epilepsies. PLoS Genet. 2010;6(5):e1000962.View ArticlePubMedPubMed CentralGoogle Scholar
  4. Rees E, Walters JT, Chambert KD, O’Dushlaine C, Szatkiewicz J, Richards AL, et al. CNV analysis in a large schizophrenia sample implicates deletions at 16p12.1 and SLC1A1 and duplications at 1p36.33 and CGNL1. Hum Mol Genet. 2014;23(6):1669–76.View ArticlePubMedPubMed CentralGoogle Scholar
  5. Kalscheuer VM, Tao J, Donnelly A, Hollway G, Schwinger E, Kubart S, et al. Disruption of the serine/threonine kinase 9 gene causes severe X-linked infantile spasms and mental retardation. Am J Hum Genet. 2003;72(6):1401–11.View ArticlePubMedPubMed CentralGoogle Scholar
  6. Saitsu H, Kato M, Mizuguchi T, Hamada K, Osaka H, Tohyama J, et al. De novo mutations in the gene encoding STXBP1 (MUNC18-1) cause early infantile epileptic encephalopathy. Nat Genet. 2008;40(6):782–8.View ArticlePubMedGoogle Scholar
  7. Mefford HC, Yendle SC, Hsu C, Cook J, Geraghty E, McMahon JM, et al. Rare copy number variants are an important cause of epileptic encephalopathies. Ann Neurol. 2011;70(6):974–85.View ArticlePubMedPubMed CentralGoogle Scholar
  8. Bartnik M, Szczepanik E, Derwinska K, Wisniowiecka-Kowalnik B, Gambin T, Sykulski M, et al. Application of array comparative genomic hybridization in 102 patients with epilepsy and additional neurodevelopmental disorders. Am J Med Genet B Neuropsychiatr Genet. 2012;159B(7):760–71.View ArticlePubMedGoogle Scholar
  9. Mullen SA, Carvill GL, Bellows S, Bayly MA, Trucks H, Lal D, et al. Copy number variants are frequent in genetic generalized epilepsy with intellectual disability. Neurology. 2013;81(17):1507–14.View ArticlePubMedPubMed CentralGoogle Scholar
  10. Striano P, Coppola A, Paravidino R, Malacarne M, Gimelli S, Robbiano A, et al. Clinical significance of rare copy number variations in epilepsy: a case–control survey using microarray-based comparative genomic hybridization. Arch Neurol. 2012;69(3):322–30.View ArticlePubMedGoogle Scholar
  11. Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature. 2007;447(7145):661–78.View ArticleGoogle Scholar
  12. Wang K, Li M, Hadley D, Liu R, Glessner J, Grant SF, et al. PennCNV: an integrated hidden Markov model designed for high-resolution copy number variation detection in whole-genome SNP genotyping data. Genome Res. 2007;17(11):1665–74.View ArticlePubMedPubMed CentralGoogle Scholar
  13. QuickCalcs. GraphPad Software Inc, La Jolla, CA. http://www.graphpad.com/quickcalcs/. Accessed 25 March 2016.
  14. Miller DT, Adam MP, Aradhya S, Biesecker LG, Brothman AR, Carter NP, et al. Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. Am J Hum Genet. 2010;86(5):749–64.View ArticlePubMedPubMed CentralGoogle Scholar
  15. Pollard KS, Hubisz MJ, Rosenbloom KR, Siepel A. Detection of nonneutral substitution rates on mammalian phylogenies. Genome Res. 2010;20(1):110–21.View ArticlePubMedPubMed CentralGoogle Scholar
  16. Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc. 2009;4(7):1073–81. SIFT, http://sift.bii.a-star.edu.sg/.View ArticlePubMedGoogle Scholar
  17. Grantham R. Amino acid difference formula to help explain protein evolution. Science. 1974;185(4154):862–4.View ArticlePubMedGoogle Scholar
  18. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, et al. A method and server for predicting damaging missense mutations. Nat Methods. 2010;7(4):248–9. PolyPhen-2, http://genetics.bwh.harvard.edu/pph2/.View ArticlePubMedPubMed CentralGoogle Scholar
  19. Kircher M, Witten DM, Jain P, O’Roak BJ, Cooper GM, Shendure J. A general framework for estimating the relative pathogenicity of human genetic variants. Nat Genet. 2014;46(3):310–5. http://cadd.gs.washington.edu/.View ArticlePubMedPubMed CentralGoogle Scholar
  20. Exome Aggregation Consortium (ExAC). Cambridge, MA. http://exac.broadinstitute.org. Accessed 25 March 2016.
  21. dbSNP. National Center for Biotechnology Information, Bethesda, MD. http://0-www.ncbi.nlm.nih.gov.brum.beds.ac.uk/SNP. Accessed 25 March 2016.
  22. ClinVar. National Center for Biotechnology Information, Bethesda, MD. http://0-www.ncbi.nlm.nih.gov.brum.beds.ac.uk/clinvar. Accessed 25 March 2016.
  23. Meng H, Xu HQ, Yu L, Lin GW, He N, Su T, et al. The SCN1A mutation database: updating information and analysis of the relationships among genotype, functional alteration, and phenotype. Hum Mutat. 2015;36(6):573–80. http://www.gzneurosci.com/scn1adatabase/.View ArticlePubMedGoogle Scholar
  24. NCBI Reference Sequence Database, http://0-www.ncbi.nlm.nih.gov.brum.beds.ac.uk/refseq/. Accessed 25 March 2016.
  25. Kleefstra T, Kramer JM, Neveling K, Willemsen MH, Koemans TS, Vissers LE, et al. Disruption of an EHMT1-associated chromatin-modification module causes intellectual disability. Am J Hum Genet. 2012;91(1):73–82.View ArticlePubMedPubMed CentralGoogle Scholar
  26. Talkowski ME, Mullegama SV, Rosenfeld JA, van Bon BW, Shen Y, Repnikova EA, et al. Assessment of 2q23.1 microdeletion syndrome implicates MBD5 as a single causal locus of intellectual disability, epilepsy, and autism spectrum disorder. Am J Hum Genet. 2011;89(4):551–63.View ArticlePubMedPubMed CentralGoogle Scholar
  27. Williams SR, Mullegama SV, Rosenfeld JA, Dagli AI, Hatchwell E, Allen WP, et al. Haploinsufficiency of MBD5 associated with a syndrome involving microcephaly, intellectual disabilities, severe speech impairment, and seizures. Eur J Hum Genet. 2010;18(4):436–41.View ArticlePubMedPubMed CentralGoogle Scholar
  28. Noh GJ, Graham Jr JM. 2q23.1 microdeletion of the MBD5 gene in a female with seizures, developmental delay and distinct dysmorphic features. Eur J Med Genet. 2012;55(1):59–62.View ArticlePubMedGoogle Scholar
  29. Hodge JC, Mitchell E, Pillalamarri V, Toler TL, Bartel F, Kearney HM, et al. Disruption of MBD5 contributes to a spectrum of psychopathology and neurodevelopmental abnormalities. Mol Psychiatry. 2014;19(3):368–79.View ArticlePubMedPubMed CentralGoogle Scholar
  30. Kleefstra T, Brunner HG, Amiel J, Oudakker AR, Nillesen WM, Magee A, et al. Loss-of-function mutations in euchromatin histone methyl transferase 1 (EHMT1) cause the 9q34 subtelomeric deletion syndrome. Am J Hum Genet. 2006;79(2):370–7.View ArticlePubMedPubMed CentralGoogle Scholar
  31. Kleefstra T, van Zelst-Stams WA, Nillesen WM, Cormier-Daire V, Houge G, Foulds N, et al. Further clinical and molecular delineation of the 9q subtelomeric deletion syndrome supports a major contribution of EHMT1 haploinsufficiency to the core phenotype. J Med Genet. 2009;46(9):598–606.View ArticlePubMedGoogle Scholar
  32. Matthews E, Labrum R, Sweeney MG, Sud R, Haworth A, Chinnery PF, et al. Voltage sensor charge loss accounts for most cases of hypokalemic periodic paralysis. Neurology. 2009;72(18):1544–7.View ArticlePubMedPubMed CentralGoogle Scholar
  33. Zangaladze A, Asadi-Pooya AA, Ashkenazi A, Sperling MR. Sporadic hemiplegic migraine and epilepsy associated with CACNA1A gene mutation. Epilepsy Behav. 2010;17(2):293–5.View ArticlePubMedGoogle Scholar
  34. Groen JL, Andrade A, Ritz K, Jalalzadeh H, Haagmans M, Bradley TE, et al. CACNA1B mutation is linked to unique myoclonus-dystonia syndrome. Hum Mol Genet. 2015;24(4):987–93.View ArticlePubMedPubMed CentralGoogle Scholar
  35. Chen Y, Lu J, Pan H, Zhang Y, Wu H, Xu K, et al. Association between genetic variation of CACNA1H and childhood absence epilepsy. Ann Neurol. 2003;54(2):239–43.View ArticlePubMedGoogle Scholar
  36. Heron SE, Khosravani H, Varela D, Bladen C, Williams TC, Newman MR, et al. Extended spectrum of idiopathic generalized epilepsies associated with CACNA1H functional variants. Ann Neurol. 2007;62(6):560–8.View ArticlePubMedGoogle Scholar
  37. Girirajan S, Dennis MY, Baker C, Malig M, Coe BP, Campbell CD, et al. Refinement and discovery of new hotspots of copy-number variation associated with autism spectrum disorder. Am J Hum Genet. 2013;92(2):221–37.View ArticlePubMedPubMed CentralGoogle Scholar
  38. Sebat J, Lakshmi B, Malhotra D, Troge J, Lese-Martin C, Walsh T, et al. Strong association of de novo copy number mutations with autism. Science. 2007;316(5823):445–9.View ArticlePubMedPubMed CentralGoogle Scholar
  39. Lang B, Pu J, Hunter I, Liu M, Martin-Granados C, Reilly TJ, et al. Recurrent deletions of ULK4 in schizophrenia: a gene crucial for neuritogenesis and neuronal motility. J Cell Sci. 2014;127(Pt 3):630–40.View ArticlePubMedGoogle Scholar
  40. Weiss LA, Shen Y, Korn JM, Arking DE, Miller DT, Fossdal R, et al. Association between microdeletion and microduplication at 16p11.2 and autism. N Engl J Med. 2008;358(7):667–75.View ArticlePubMedGoogle Scholar
  41. Shinawi M, Liu P, Kang SH, Shen J, Belmont JW, Scott DA, et al. Recurrent reciprocal 16p11.2 rearrangements associated with global developmental delay, behavioural problems, dysmorphism, epilepsy, and abnormal head size. J Med Genet. 2010;47(5):332–41.View ArticlePubMedPubMed CentralGoogle Scholar
  42. Reinthaler EM, Lal D, Lebon S, Hildebrand MS, Dahl HH, Regan BM, et al. 16p11.2 600 kb Duplications confer risk for typical and atypical Rolandic epilepsy. Hum Mol Genet. 2014;23(22):6069–80.View ArticlePubMedGoogle Scholar
  43. Mantegazza M, Gambardella A, Rusconi R, Schiavon E, Annesi F, Cassulini RR, et al. Identification of an Nav1.1 sodium channel (SCN1A) loss-of-function mutation associated with familial simple febrile seizures. Proc Natl Acad Sci U S A. 2005;102(50):18177–82.View ArticlePubMedPubMed CentralGoogle Scholar
  44. Claes L, Del-Favero J, Ceulemans B, Lagae L, Van Broeckhoven C, De Jonghe P. De novo mutations in the sodium-channel gene SCN1A cause severe myoclonic epilepsy of infancy. Am J Hum Genet. 2001;68(6):1327–32.View ArticlePubMedPubMed CentralGoogle Scholar
  45. Escayg A, MacDonald BT, Meisler MH, Baulac S, Huberfeld G, An-Gourfinkel I, et al. Mutations of SCN1A, encoding a neuronal sodium channel, in two families with GEFS + 2. Nat Genet. 2000;24(4):343–5.View ArticlePubMedGoogle Scholar
  46. Harkin LA, McMahon JM, Iona X, Dibbens L, Pelekanos JT, Zuberi SM, et al. The spectrum of SCN1A-related infantile epileptic encephalopathies. Brain. 2007;130(Pt 3):843–52.View ArticlePubMedGoogle Scholar
  47. Depienne C, Trouillard O, Saint-Martin C, Gourfinkel-An I, Bouteiller D, Carpentier W, et al. Spectrum of SCN1A gene mutations associated with Dravet syndrome: analysis of 333 patients. J Med Genet. 2009;46(3):183–91.View ArticlePubMedGoogle Scholar
  48. Vanoye CG, Gurnett CA, Holland KD, George Jr AL, Kearney JA. Novel SCN3A variants associated with focal epilepsy in children. Neurobiol Dis. 2014;62:313–22.View ArticlePubMedGoogle Scholar
  49. Shi X, Yasumoto S, Kurahashi H, Nakagawa E, Fukasawa T, Uchiya S, et al. Clinical spectrum of SCN2A mutations. Brain Dev. 2012;34(7):541–5.View ArticlePubMedGoogle Scholar
  50. Singh NA, Pappas C, Dahle EJ, Claes LR, Pruess TH, De Jonghe P, et al. A role of SCN9A in human epilepsies, as a cause of febrile seizures and as a potential modifier of Dravet syndrome. PLoS Genet. 2009;5(9):e1000649.View ArticlePubMedPubMed CentralGoogle Scholar
  51. Carranza Rojo D, Hamiwka L, McMahon JM, Dibbens LM, Arsov T, Suls A, et al. De novo SCN1A mutations in migrating partial seizures of infancy. Neurology. 2011;77(4):380–3.View ArticlePubMedPubMed CentralGoogle Scholar
  52. Lim BC, Hwang H, Kim H, Chae JH, Choi J, Kim KJ, et al. Epilepsy phenotype associated with a chromosome 2q24.3 deletion involving SCN1A: Migrating partial seizures of infancy or atypical Dravet syndrome? Epilepsy Res. 2015;109:34–9.View ArticlePubMedGoogle Scholar
  53. Suls A, Claeys KG, Goossens D, Harding B, Van Luijk R, Scheers S, et al. Microdeletions involving the SCN1A gene may be common in SCN1A-mutation-negative SMEI patients. Hum Mutat. 2006;27(9):914–20.View ArticlePubMedGoogle Scholar
  54. Rudd MK, Keene J, Bunke B, Kaminsky EB, Adam MP, Mulle JG, et al. Segmental duplications mediate novel, clinically relevant chromosome rearrangements. Hum Mol Genet. 2009;18(16):2957–62.View ArticlePubMedPubMed CentralGoogle Scholar
  55. Yu HE, Hawash K, Picker J, Stoler J, Urion D, Wu BL, et al. A recurrent 1.71 Mb genomic imbalance at 2q13 increases the risk of developmental delay and dysmorphism. Clin Genet. 2012;81(3):257–64.View ArticlePubMedGoogle Scholar
  56. Heinzen EL, Radtke RA, Urban TJ, Cavalleri GL, Depondt C, Need AC, et al. Rare deletions at 16p13.11 predispose to a diverse spectrum of sporadic epilepsy syndromes. Am J Hum Genet. 2010;86(5):707–18.View ArticlePubMedPubMed CentralGoogle Scholar
  57. Ullmann R, Turner G, Kirchhoff M, Chen W, Tonge B, Rosenberg C, et al. Array CGH identifies reciprocal 16p13.1 duplications and deletions that predispose to autism and/or mental retardation. Hum Mutat. 2007;28(7):674–82.View ArticlePubMedGoogle Scholar
  58. Mefford HC, Cooper GM, Zerr T, Smith JD, Baker C, Shafer N, et al. A method for rapid, targeted CNV genotyping identifies rare variants associated with neurocognitive disease. Genome Res. 2009;19(9):1579–85.View ArticlePubMedPubMed CentralGoogle Scholar
  59. Ingason A, Rujescu D, Cichon S, Sigurdsson E, Sigmundsson T, Pietilainen OP, et al. Copy number variations of chromosome 16p13.1 region associated with schizophrenia. Mol Psychiatry. 2011;16(1):17–25.View ArticlePubMedPubMed CentralGoogle Scholar
  60. Kirov G, Grozeva D, Norton N, Ivanov D, Mantripragada KK, Holmans P, et al. Support for the involvement of large copy number variants in the pathogenesis of schizophrenia. Hum Mol Genet. 2009;18(8):1497–503.View ArticlePubMedPubMed CentralGoogle Scholar
  61. Ramalingam A, Zhou XG, Fiedler SD, Brawner SJ, Joyce JM, Liu HY, et al. 16p13.11 duplication is a risk factor for a wide spectrum of neuropsychiatric disorders. J Hum Genet. 2011;56(7):541–4.View ArticlePubMedGoogle Scholar
  62. Gillentine MA, Schaaf CP. The human clinical phenotypes of altered CHRNA7 copy number. Biochem Pharmacol. 2015;97(4):352–62.View ArticlePubMedGoogle Scholar
  63. Kashevarova AA, Nazarenko LP, Schultz-Pedersen S, Skryabin NA, Salyukova OA, Chechetkina NN, et al. Single gene microdeletions and microduplication of 3p26.3 in three unrelated families: CNTN6 as a new candidate gene for intellectual disability. Mol Cytogenet. 2014;7(1):97.View ArticlePubMedPubMed CentralGoogle Scholar
  64. Te Weehi L, Maikoo R, Mc Cormack A, Mazzaschi R, Ashton F, Zhang L, et al. Microduplication of 3p26.3 implicated in cognitive development. Case Rep Genet. 2014;201:295359.Google Scholar
  65. van Daalen E, Kemner C, Verbeek NE, van der Zwaag B, Dijkhuizen T, Rump P, et al. Social Responsiveness Scale-aided analysis of the clinical impact of copy number variations in autism. Neurogenetics. 2011;12(4):315–23.View ArticlePubMedPubMed CentralGoogle Scholar
  66. Catarino CB, Liu JY, Liagkouras I, Gibbons VS, Labrum RW, Ellis R, et al. Dravet syndrome as epileptic encephalopathy: evidence from long-term course and neuropathology. Brain. 2011;134(Pt 10):2982–3010.View ArticlePubMedPubMed CentralGoogle Scholar

Copyright

Advertisement